Skip to main content
. 2016 Feb 17;3(1):47–59. doi: 10.2217/mmt.15.40

Table 2. . Clinical trials for NRAS mutant melanoma.

Clinical trial number Phase Population Status Drug(s)/notes
NCT01781572 Ib/II Locally advanced or metastatic NRAS mutant melanoma Currently recruiting Binimetinib + ribociclib (LEE011) [101]
NCT02065063 I/II Multiple cancers Currently recruiting Trametinib + palbociclib [102]
NCT01363232 Ib/II Multiple cancers Ongoing, no longer recruiting PI3K inhibitor BKM120 + the MEK1/2 inhibitor MEK162 [103]
NCT01337765 Ib Multiple cancers CLOSED PI3K/mTOR inhibitor BEZ235 in combination with the MEK1/2 inhibitor MEK162 [104]
NCT01449058 Ib Multiple cancers Currently recruiting BYL719 plus MEK162 [105]
NCT01941927 II BRAF wild-type mutation melanoma Ongoing, no longer recruiting Trametinib (2 mg) in combination with uprosertib GSK2141795 (25 mg) oral daily [106]
NCT01693068 II NRAS mutant locally advanced or metastasis malignant cutaneous melanoma Ongoing, no longer recruiting Pimasertib (MEK 1/2 inhibitor) vs dacarbazine [107]
NCT01763164 III Metastatic or unresectable cutaneous melanoma (NRAS Q61 mutant only) Currently recruiting NEMO: Phase III trial of binimetinib (MEK162) vs dacarbazine [108]
NCT01352273 Ib Adult patients with advanced solid tumors harboring RAS or BRAFV600E mutations Completed MEK162 and RAF265 in adult patients with advanced solid tumors harboring RAS or BRAFV600E mutations [109]